Table 2.
Clinical outcomes of COVID-19-related to DPP4i treatment
| Author | Death | ICU admission | Mechanical Ventilation | ICU admission and/or death | ICU admission, mechanical ventilation, death | Mechanical Ventilation and/or death | Disease severity |
|---|---|---|---|---|---|---|---|
| Solerte | adj OR 0.23 (0.12–0.46) | HR 0.51 (0.27–0.95) | HR 0.27 (0.11–0.62) | ||||
| Mirani | adj HR 0.13 (0.02–0.92) | OR 0.54 (0.11–2.70) | |||||
| Rhee | adj OR 0.362 (0.14–0.97) | ||||||
| Yan | adj OR 0.32 (0.02–2.18) | ||||||
| Kim | adj OR 1.47 (0.45–4.78) | ||||||
| Chen | adj OR 1.48 (0.40, 5.53) | ||||||
| Silverii | RR 1.0 (0.51–2.14) | ||||||
| Fadini | RR 0.80 (0.12–5.54) | OR 1.74 (0.62–4.90) | |||||
| Cariou | OR 0.85 (0.55–1.32) | OR 1.01 (0.75, 1.34) | |||||
| Pérez-Belmonte | adj OR 1.05 (0.67–2.11) | OR 1.12 (0.65–1.95) | |||||
| Dalan | adj RR 4.07, (1.42–11.66) | adj RR 60.2 (3.17–1140.1) |
ICU intensive care unit, Adj adjusted, OR odds ratio, HR hazard ratio, RR relative risk